Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Davis
Dates
study started
completion around

Description

Summary

This phase II trial studies how well ibrutinib works in treating patients with stage IV melanoma of the skin that has not responded to previous treatment. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Official Title

A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers With Response and Resistance

Details

Keywords

Metastatic Melanoma, Recurrent Cutaneous Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Melanoma, Cutaneous Malignant Melanoma, Skin Neoplasms, Ibrutinib, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study

Eligibility

Locations

  • University of California Davis Comprehensive Cancer Center
    Sacramento California 95817 United States
  • Los Angeles General Medical Center
    Los Angeles California 90033 United States
  • USC / Norris Comprehensive Cancer Center
    Los Angeles California 90033 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Cancer Institute (NCI)
ID
NCT02581930
Phase
Phase 2 Skin Cancer/Melanoma Research Study
Study Type
Interventional
Participants
About 18 people participating
Last Updated